Cargando…
Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
There is currently a lack of biological tools to study the replication cycle and pathogenesis of SARS-CoV-2, the etiological agent of COVID-19. Repurposing the existing tools, including antibodies of SARS-CoV, is an effective way to accelerate the development of therapeutics for COVID-19. Here, we e...
Autores principales: | Bates, Timothy A., Weinstein, Jules B., Farley, Scotland E., Leier, Hans C., Messer, William B., Tafesse, Fikadu G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402058/ https://www.ncbi.nlm.nih.gov/pubmed/32766589 http://dx.doi.org/10.1101/2020.07.30.229377 |
Ejemplares similares
-
Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
por: Bates, Timothy A., et al.
Publicado: (2021) -
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
por: Weinstein, Jules B., et al.
Publicado: (2022) -
A global lipid map reveals host dependency factors conserved across SARS-CoV-2 variants
por: Farley, Scotland E., et al.
Publicado: (2022) -
The time between vaccination and infection impacts immunity against SARS-CoV-2 variants
por: Bates, Timothy A., et al.
Publicado: (2023) -
Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum
por: Bates, Timothy A., et al.
Publicado: (2021)